Table 1 Baseline clinical characteristics

Age, y

67.8 ± 10.5

66.7 ± 9.8

0.654

Women, n (%)

20(50)

14(35)

0.258

Diabetes duration, months (95 % CI)

48(6-240)

38.5(3-218)

0.145

Body mass index, kg/m2

27.7 ± 4.1

25.7 ± 4.3

0.038

Abdominal girth, cm

88.7 ± 14.3

85.9 ± 15.6

0.469

Current smoking

6(15)

4(10)

0.762

Regular alcohol drinkers

13(33)

17(43)

0.489

NYHA functional class

Class I, n (%)

17(43)

17(43)

1.000

Class II, n (%)

23(58)

22(55)

Class III, n (%)

0(0)

1(3)

Grades of Diastolic Dysfunction

0

1 (2.6)

3 (7.5)

0.0987

1

31 (79.5)

34 (85.0)

2

7 (17.9)

3 (7.5)

Diabetes complication+

7(18)

3(8)

0.311

Diabetic retinopathy

4(10)

2(5)

0.675

Diabetic nephropathy

3(8)

0(0)

0.241

Diabetic neuropathy

2(5)

0(0)

0.494

Hypertension

37(93)

32(80)

0.193

Hyperuricemia

31(78)

31(78)

1.000

Hyperlipidemia

5(13)

4(10)

1.000

Renal disturbance

7(18)

1(3)

0.057

Mean eGFR

74.8 ± 21.7

70.5 ± 15.3

0.304

Cerebrovascular disease

3(8)

1(3)

0.615

Myocardial infarction

5(13)

2(5)

0.432

Peripheral artery disease

3(8)

1(3)

0.615

Anti-diabetic drugs

Pioglitazone

14(35)

18(45)

0.494

Sulfonylurea

6(15)

3(8)

0.481

Metformin

7(18)

1(3)

0.057

α-GI

1(3)

0(0)

1.000

Antihypertensive drugs

ARB

28(70)

27(68)

1.000

Calcium channel blocker

26(65)

22(55)

0.494

Diuretics

15(38)

10(25)

0.335

Others

11(28)

10(25)

1.000

ACE-I

2(5)

3(8)

α-blocker

4(10)

1(3)

β-blocker

6(15)

4(10)

αβ-blocker

1(3)

1(3)

Aldosterone antagonist

2(5)

1(3)

Antihyperlipidemic drugs

Statins

24(60)

22(55)

0.821

Fibrate

2(5)

2(5)

1.000

Ezetimibe

5(13)

6(15)

1.000

Eicosapentaenoic acid

5(13)

2(5)

0.432

Antiplatelet agent

10(25)

12(30)

0.803

Nitrates

1(3)

1(3)

1.000

Allopurinol

1(3)

4(10)

0.359

Uricosuric agents

0(0)

1(3)

1.000